Abemaciclib does not increase the corrected QT interval in healthy participants - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37337637/
Abemaciclib is an orally administered potent and selective small molecule inhibitor of cyclin dependent kinases 4 and 6, approved for advanced or metastatic breast cancer. This study aimed to use...
Conclusion: Single doses of abemaciclib, up to 400 mg, had no statistically or clinically relevant effects on QTc, and abemaciclib was well-tolerated up to a dose of 400 mg in this study.
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry - Breast Cancer Research and Treatment
Source : https://link.springer.com/article/10.1007/s10549-023-07002-1
Purpose The monarchE trial showed that the addition of abemaciclib improves efficacy in patients with high-risk early breast cancer (EBC). We analyzed the long-term outcomes of a population similar to...
Conclusion: Our study shows that the prognosis of patients eligible for the monarchE trial and treated with conventional chemotherapy and ET is dismal, with more than 40% of patients showing an iDFS event and 30% of deaths at 10 years. Looking at the pattern of relapse of patients, with a peak at years 1 till 3 but a plateau from year 4–10,...
Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37296790/
The introduction in clinical practice of selective cyclin-dependent kinase (CDK) 4/6 inhibitors improves the outcome of patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast...
Conclusions/Relevance: Our results show no major differences compared to randomized clinical trials, despite the smaller patient group. In order to have a picture of the efficacy of the treatment as close as possible to the real-world data, we believe that it would be very useful to have a collaboration between several oncology departments in...
Ribociclib-induced visual hallucination in a patient with metastatic breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37306182/
To our knowledge, this is the first reported case of hallucinations caused by ribociclib; notably, it shows that symptoms may develop in the early stage of treatment.
Discussion: To our knowledge, this is the first reported case of hallucinations caused by ribociclib; notably, it shows that symptoms may develop in the early stage of treatment.
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world - Breast Cancer Research and Treatment
Source : https://link.springer.com/article/10.1007/s10549-023-06993-1
Purpose Cyclin Dependent Kinase 4 & 6 inhibitors (CDK4 & 6i) have transformed the management of HR+, HER2− metastatic breast cancer (MBC); however, the optimal sequence of these treatments and...
Conclusions: Although retrospective and hypothesis-generating, these data demonstrate numerically longer outcomes in the subsequent LOT associated with sequential CDK4 & 6i treatment.